Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_provenance.
- NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_assertion description "[A phase II trial is ongoing to test the hypothesis that a compound, high-dose medroxyprogesterone acetate (MPA), used as an unconventional gluocorticoid, will stimulate breast cancer cells to reexpress Nm23-H1 and limit subsequent metastatic colonization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_provenance.
- NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_assertion evidence source_evidence_literature NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_provenance.
- NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_assertion SIO_000772 18698018 NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_provenance.
- NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_assertion wasDerivedFrom befree-20150227 NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_provenance.
- NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_assertion wasGeneratedBy ECO_0000203 NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_provenance.
- befree-20150227 importedOn "2015-02-27" NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_provenance.